Search results
Economic development in sub-Saharan Africa is linked to increasing obesity rates in women
Medical Xpress· 27 minutes agoThe increasing prevalence of obesity can be attributed to rising incomes, increasingly sedentary lifestyles, the adoption of western cultures and the consumption of processed ...
Obesity: Does eating chili peppers increase or decrease risk?
Medical News Today· 1 day agoChili peppers are often recognized for their slight fat-burning and metabolism-boosting properties....
Wait—Why Am I Not Losing Weight on Ozempic?
Parade· 5 hours agoOzempic is technically for the management of type 2 diabetes. The most significant "side effect" of the diabetes drug, weight loss, has made it sought...
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters via AOL· 5 hours agoEvidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart...
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
Investor's Business Daily· 2 hours agoThough Stelo is designed for people with diabetes, the over-the-counter availability almost...
'American Idol' alum Mandisa died from complications of class III obesity. Here's what that means.
Yahoo Life· 5 days agoHowever, an individual’s risk of developing cardiometabolic diseases like hypertension, stroke and ...
Analyst Report: Novo Nordisk
Argus Research via Yahoo Finance· 5 hours agoNovo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include ...
Obesity Drug Leader In Buy Zone After Huge Gains
Investor's Business Daily· 5 days agoThe stock is also a holding on IBD Leaderboard and ranks first in the ethical drugs industry group. Novo Nordisk makes products to treat and manage ...
What's the Difference Between Ozempic and Metformin, and Which One Is Right for You?
Parade via Yahoo News· 4 days agoOzempic is a GLP-1 medication approved by the FDA for treating Type 2 diabetes. "It is a brand name...
GLP-1 Discontinuation Less Common With Endocrinologists
Medscape· 11 hours agoPatients taking glucagon-like peptide 1 (GLP-1) receptor agonists for obesity appear to be...